2000
DOI: 10.1212/wnl.54.6.1218
|View full text |Cite
|
Sign up to set email alerts
|

New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2000
2000
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 200 publications
(9 citation statements)
references
References 16 publications
0
9
0
Order By: Relevance
“…In total, 30 patients with a molecular diagnosis of DM1 were recruited from the Neuromuscular and Neurological Rare Diseases Centre at San Camillo Forlanini Hospital (Rome, Italy) and from the Institute of Neurology at the Fondazione Policlinico Universitario A. Gemelli, IRCCS (Rome, Italy). In order to exclude the presence of a major cognitive impairment or mental retardation, patients had to be all suffering from a childhood, juvenile, or adulthood form of DM, as classified by the International Myotonic Dystrophy Consortium (IDMC) nomenclature (20), and they had to report a Mini Mental State Examination score (21) above 26. In addition, all patients had to show a normal level of intelligence quotient and no impairment in the comprehension ability, (16), anosognosia, or failures in school achievement.…”
Section: Participantsmentioning
confidence: 99%
“…In total, 30 patients with a molecular diagnosis of DM1 were recruited from the Neuromuscular and Neurological Rare Diseases Centre at San Camillo Forlanini Hospital (Rome, Italy) and from the Institute of Neurology at the Fondazione Policlinico Universitario A. Gemelli, IRCCS (Rome, Italy). In order to exclude the presence of a major cognitive impairment or mental retardation, patients had to be all suffering from a childhood, juvenile, or adulthood form of DM, as classified by the International Myotonic Dystrophy Consortium (IDMC) nomenclature (20), and they had to report a Mini Mental State Examination score (21) above 26. In addition, all patients had to show a normal level of intelligence quotient and no impairment in the comprehension ability, (16), anosognosia, or failures in school achievement.…”
Section: Participantsmentioning
confidence: 99%
“…The genetic defect underlying DM1 is multiple CTG repeats in the 3' untranslated region of a gene (DM1) on the long arm of the chromosome: the analysis of the CTG repeat on chromosome 19q13 [ 2 ]. Neuropathological, neuroimaging, and neurophysiological studies have demonstrated a variety of abnormalities of the central nervous system (CNS) in DM1 patients [ 3 5 ]. Magnetic resonance imaging (MRI) has been widely used to evaluate DM1.…”
Section: Introductionmentioning
confidence: 99%
“…Upon transmission to offspring the repeat length may increase and lead to a more severe disease, a mechanism known as anticipation. The broad spectrum of clinical presentations of DM1 overlap extensively with those of other disorders; and molecular testing is essential for a definitive diagnosis 6 .…”
Section: Introductionmentioning
confidence: 99%
“…standard PCR followed by fragment length analysis and Southern blot analysis 7 . The standard PCR technique, although sufficient in detecting the lower range of CTG expansions, is not reliable in amplifying repeats of over ~150 CTG repeats) and may fail to detect larger expansions when smaller alleles are preferentially amplified (allelic dropout) 6 . Therefore, samples in which only one repeat length is detected by PCR must be further analyzed for the possible presence of an expanded allele 7 .…”
Section: Introductionmentioning
confidence: 99%